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Abstract
Background: Concerns have been raised that implants used in total hip replacements (THR) could lead to
increased cancer risk. Several different materials, metals and fixation techniques are used in joint prostheses and
different types of articulation can cause an increased invasion of particles or ions into the human body.
Methods: Patients with THR registered in the Norwegian Arthroplasty Register during 1987–2009 were linked to
the Cancer registry of Norway. Patients with THR due to osteoarthritis, under the age of 75 at time of surgery, were
included. Standardized incidence ratios (SIR) were applied to compare cancer risk for THR patients to the general
population. Types of THR were divided into cemented (both components), uncemented (both components), and
hybrid (cemented femoral and uncemented acetabular components). To account for selection mechanisms, time
dependent covariates were applied in Cox-regression, adjusting for cancer risk the first 10 years after surgery. The
analyses were adjusted for age, gender and if the patient had additional THR-surgery in the same or the opposite
hip. The study follows the STROBE guidelines.
Results: Comparing patients with THR to the general population in Norway we found no differences in cancer risk.
The overall SIR for the THR-patients after 10 years follow-up was 1.02 (95% CI: 0.97–1.07). For cemented THR, the SIR
after 10 years follow-up was 0.99 (95% CI: 0.94–1.05), for uncemented, 1.16 (95% CI: 1.02–1.30), and for hybrid 1.12
(95% CI: 0.91–1.33). Adjusted Cox analyses showed that patients with uncemented THRs had an elevated risk for
cancer (hazard ratio: HR = 1.24, 95% CI: 1.05–1.46, p = 0.009) when compared to patients with cemented THRs after
10 years follow-up. Stratified by gender the increased risk was only present for men. The risk for patients with
hybrid THRs was not significantly increased (HR = 1.07, 95% CI: 0.85–1.35, p = 0.55) compared to patients with
cemented THRs.
Conclusions: THR patients had no increased risk for cancer compared to the general population. We found,
however, that receiving an uncemented THR was associated with a small increased risk for cancer compared to
cemented THR in males, but that this may be prone to unmeasured confounding.
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Background
In total hip replacement (THR) surgery, implants con-
sisting of metals, polymers, and ceramics are inserted,
some of which are fixated by means of bone cement.
The numbers of metals and other materials, and the var-
iety of sizes and bearing surfaces used in these implants
over the years, have been substantial. Concerns have
been raised whether the insertion of implants might lead
to subsequent malignancies [1–4]. Tumours could hypo-
thetically develop at the implant site, due to local reac-
tions, or elsewhere in the body, caused by systemic
influences. In animal studies, different materials have been
used to model cancer development, but questions have
been raised whether biomaterial-related tumours in ani-
mals have relevance to humans [5]. Most studies have
found no increased cancer risk after THRs compared to
the general population [6–16]. In a meta-analysis, Visuri
and colleagues observed a decreased cancer risk for pa-
tients with arthroplasties [17]. Another meta-analysis did
not confirm an overall increased cancer risk after THR
and Total Knee Arthroplasty (TKA), but described an ele-
vated risk for prostate cancer and melanomas [18]. A
group from Sweden has reported an increased cancer risk
among patients who had received a TKA due to osteoarth-
ritis and rheumatoid arthritis, and also reported a latency
effect for cancer after insertion of joint replacements [19].
In the present study, we have linked data on THRs
from the Norwegian Arthroplasty Register (NAR) to the
Cancer Registry of Norway (CRN). The primary aim of
the study was to determine if there were differences in
the long term (after 10 years) cancer risk according to
types of prosthesis fixation; cemented (both femoral and
acetabular components cemented), uncemented (both
femoral and acetabular components uncemented), and
hybrid (cemented femoral and uncemented acetabular
component).
Methods
In this prospective cohort study, follow-up time was
measured from insertion of the initial prosthesis and
until cancer, emigration, death, or December 31st 2009
(end of study), whichever came first.
The Norwegian Arthroplasty Register (NAR) started
registration of total hip replacements (THR) in Septem-
ber 1987 [20]. More than 95% of patients receiving a
THR are reported to the NAR [21, 22]. Patients regis-
tered with primary THR, from 1987 to 2009 with known
prosthesis fixations, osteoarthritis, under the age of 75 at
time of surgery, were followed from their first/initial op-
eration. Since this study looks at the late (after 10 years)
risk for cancer, patients older than 75 years were ex-
cluded. The selected patients were linked to the Cancer
Registry of Norway (CRN) using the 11-digit personal
identification number unique for all Norwegian citizens.
The CRN was established in 1953 and registration of
new cancer cases is compulsory. The registry has infor-
mation on type of malignancy, date of diagnosis and ini-
tial treatment and demographics on 99% of all cancer
patients in Norway [23, 24]. THR patients with cancer
prior to the THR were excluded from the analysis.
Hence, 41,402 patients were included. In the files from
the CRN, ICD-7 code 189 (basal cell carcinoma) was not
included.
Type of fixation was coded as fully cemented, fully
uncemented, and hybrids (cemented femoral and unce-
mented acetabular components). THR patients with re-
versed hybrids (uncemented femoral and cemented
acetabular components) were excluded due to few obser-
vations and short follow-up. The outcome variable of
this study was the incidence of cancer occurring 10 years
after insertion of THR. The Cancer Registry of Norway
is a mandatory national health registry, regulated by law.
All hospitals, laboratories, and general practitioners are
obligated to report new cancer cases to the registry
within 2 months. The Norwegian Arthroplasty Register
(NAR), started in 1987, is a voluntary register licensed
by the Data Inspectorate of Norway (16/01622–3). Pa-
tients give a written informed consent to be included in
the registry. The operating surgeon reports the operation
to the registry on a one-page standard form. The present
study was approved by the Regional Committee for
Medical and Health Research Ethics, Western Norway
(170.06) and The Norwegian Data Protection Authority
(06/01218–2). The study is reported according to the
STROBE guidelines.
Standardized incidence ratio (SIR) was calculated to
quantify the difference in cancer risk between THR pa-
tients and the population with corresponding age, gen-
der and calendar year. The SIR will equal the hazard
rate for patients divided with the hazard for the corre-
sponding population [25, 26]. SIRs after 10 years follow-
up were the main focus, but SIRs for the complete
follow-up and SIRs before 10 years follow-up were also
examined. SIR before 10 years follow-up may indicate
possible selections of healthier or sicker patients for the
different types of prosthesis. A SIR below 1 can indicate
healthier patients than the population, while a SIR above
1 indicate sicker patients.
A Cox proportional hazards regression model, for the
risk for cancer after 10 years follow-up, including a time-
dependent indicator to adjust for the hazard for cancer
in the first decade was set up to adjust for potential se-
lection mechanisms. Hence, in this model, the hazard ra-
tios after 10 years follow-up between the different types
of prosthesis fixation were adjusted for the baseline haz-
ards (cancer risk) the first 10 years follow-up. This
difference-in-difference model minimizes the effect of
unknown covariates. The regression models were
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adjusted for gender, age at operation, and time-
dependent covariates for time to a contralateral THR
and/or a revision operation. For testing of the propor-
tionality assumption, a test of the Schoenfeld residuals
after fitting the Cox-model was performed. To see if the
results were consistent within subgroups, the analysis
was stratified based on the age-categories and gender.
Follow-up time was measured from insertion of the ini-
tial prosthesis and until cancer, emigration, death, or
December 31st 2009 (end of study), whichever came
first. Median follow-up was calculated using the inverse
Kaplan-Meier method [27]. IBM-SPSS version 22 (IBM-
SPSS, Chicago Ill), Stata (version 13-IC), and Fortran
[26] were used for the statistical analyses. P-values less
than 0.05 (5%) were considered statistically significant.
Results
There were 13,954 (34%) males and 27,448 (66%) fe-
males, with a mean age of 65 (SD = 7) and 66 (SD = 7)
respectively. Of the THR patients, 6167 were diagnosed
with at least one cancer after THR, 1789 of these occur-
ring more than 10 years after the first primary hip im-
plant (Table 1). There was huge variation in the types of
cancer and the most common single cancer type after
10 years follow-up was prostate cancer (257 males) and
breast cancer (183 females) (Table 2). Total person years
in the study were 453,950 and median follow-up was
11.9 years (Table 1). Uncemented THRs were predomin-
antly given to younger and healthier individuals. For the
included patients, the mean age for uncemented THR
was 58.1 (sd = 8.3) years, for cemented 67.0 (sd = 5.9)
Table 1 Number of hips, cases of cancer, males and follow-up time
Number of hips Number of cancers Percent males Person years Median follow-up Hips after 10 years Cancer after 10 years
Total
Cemented 32,534 5060 32 361,924 12.2 16,653 1417
Uncemented 6679 743 41 65,634 9.8 2907 262
Hybrid 2189 364 36 26,392 13.3 1391 110
All fixations 41,402 6167 34 453,950 11.9 20,951 1789
< 55 years
Cemented 1138 89 41 11,602 9.3 478 34
Uncemented 1967 139 46 22,174 11.9 1106 69
Hybrid 269 18 45 2705 10.6 144 6
All fixations 3374 246 44 36,481 10.8 1728 109
55–64 years
Cemented 8480 1119 34 92,572 11.2 4167 391
Uncemented 3219 418 40 31,528 9.9 1398 151
Hybrid 801 172 36 9260 12.4 490 38
All fixations 12,500 1664 36 133,360 11.1 6055 580
65–74 years
Cemented 22,916 3852 31 257,750 12.8 12,008 992
Uncemented 1493 186 38 11,932 7.2 403 42
Hybrid 1119 219 34 14,427 15.0 757 66
All fixations 25,528 4257 31 284,109 12.6 13,168 1100
Men
Cemented 10,423 2037 100 112,322 12.2 5058 537
Uncemented 2748 343 100 26,690 9.8 1201 129
Hybrid 783 162 100 8993 12.8 472 44
All fixations 13,954 2542 100 148,005 11.9 6731 710
Women
Cemented 22,111 3023 0 249,601 12.2 11,595 880
Uncemented 3931 400 0 38,944 9.8 1706 133
Hybrid 1406 202 0 17,399 13.7 919 65
All fixations 27,448 3625 0 305,945 12.0 14,220 1079
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years, while for hybrid prostheses mean age was 63.3
(sd = 7.2) years.
For THR-patients the overall standardized incidence
ratio after 10 years follow-up was not statistically signifi-
cantly different from the general population in Norway.
SIR = 1.02, 95% CI: 0.97–1.07.
After 10 years follow-up, SIR for cemented prostheses
was 0.99 (95% CI: 0.94–1.05), for uncemented, 1.16 (95%
CI: 1.02–1.30) and for hybrid 1.12 (95% CI: 0.91 1.33)
(Table 3). In the regression model we found that pa-
tients with uncemented prostheses, had an increased risk
for cancer after 10 years follow-up compared to cemen-
ted prostheses (HR = 1.24, 95% CI: 1.05–1.46, p = 0.009).
Patients with hybrid prostheses were not statistically sig-
nificant from those with cemented prostheses (HR =
1.07, 95% CI: 0.85–1.35, p = 0.55). Both SIR and the Cox
model gave statistically significant increased risk for
cancer 10 years after receiving an uncemented total hip
replacement (THR).
Testing of the proportionality assumption in the
regression model showed that in a model with no time-
dependent covariates, the dummy variable for uncemen-
ted (versus cemented) implants interacted with time
(p = 0.008). However, for the fully adjusted model, with
all the mentioned time-dependent covariates, none of
the covariates had an interaction with time (overall p =
0.96).
Stratified by age categories, there were no significant
differences in risk for cancer between the different types
of fixation (Table 3). Males with uncemented THRs had
an increased risk for cancer compared to males with
cemented THRs (HR = 1.41, 95% CI: 1.11–1.80, p =
0.004), while this was not found for females (HR = 1.09,
95% CI: 0.87–1.36, p = 0.47). Stratified by gender and
Table 2 Types of cancer following a total hip replacement, with more than 100 observed cases, before and after 10 years follow-up
Before 10 years After 10 years Total
Cancer type (ICD-7) Cemented Uncemented Hybrid Cemented Uncemented Hybrid
Men 1500 214 118 537 129 44 2542
Prostate (177) 547 66 37 191 51 15 907
Large intestine (153) 142 18 11 52 6 4 233
Bronchus and trachea (162) 128 20 12 43 13 3 219
Skin (191) 94 13 2 44 10 4 167
Bladder and urinary organs (181) 89 10 10 37 5 3 154
Haematopoietic (207) 72 11 7 27 8 0 125
Malignant melanoma (190) 64 10 7 17 2 4 104
Rectum (154) 64 11 4 16 5 1 101
Others (n < 100) 300 55 28 110 29 10 532
Women 2143 267 136 880 133 66 3625
Breast (170) 395 66 30 149 24 10 674
Large intestine (153) 328 32 24 131 15 9 539
Bronchus and trachea (162) 174 19 5 75 9 5 287
Uteri (171 & 172) 168 31 12 54 8 4 277
Skin (191) 116 5 2 74 5 8 210
Rectum (154) 103 15 6 31 9 2 166
Haematopoietic (207) 92 6 9 47 3 1 158
Malignant melanoma (190) 98 19 7 24 5 4 157
Pancreas (157) 74 8 3 41 11 3 140
Ovary (175) 92 7 3 28 3 2 135
Brain and nervous system (193) 66 11 5 29 8 2 121
Kidney (180) 76 8 5 24 2 1 116
Lymphatic (206) 53 7 11 26 10 4 111
Bladder and urinary organs (181) 61 6 3 25 5 0 100
Other (n < 100) 247 27 11 122 16 11 434
Total 3643 481 254 1417 262 110 6167
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age categories we found no statistically significant differ-
ences comparing uncemented and hybrid prostheses to
cemented prostheses (Table 4).
Discussion
There has been focus on the risk for cancer after inser-
tion of joint replacements [2–4]. The majority of studies
are from the national arthroplasty registries in Finland
[9, 10, 12, 15, 16], Scotland [6], England and Wales [14],
and Sweden [19]. All but one of these studies conclude
that there is no (or a negligible) increased risk for cancer
after insertion of joint replacements. On the other hand,
Wagner and colleagues have reported an overall in-
creased cancer risk for total knee arthroplasty (TKA) pa-
tients compared to the general population. In addition,
they reported findings of specific cancer types, which
they argue can be a result of TKA exposure [19]. Our
study supports previous findings showing no overall in-
creased risk for cancer after THR, neither before nor
after 10 years follow-up. For uncemented THRs we
found an association with a small increased risk for can-
cer for males.
There are limitations in this study. As shown by Lie
and colleagues [28], patients with a THR have reduced
overall mortality compared to the general population,
while THR patients under 60 years have increased mor-
tality and patients over 80 years of age have considerably
reduced mortality compared to the population in gen-
eral. Furthermore, uncemented prostheses have predom-
inantly been given to younger and healthier patients,
while cemented prostheses have been given to elderly
and frailer patients [29]. Consequently, adjusting for the
risk for cancer, the first 10 years after primary THR (dif-
ference-in-difference model) would adjust for (unknown)
risk factors contributing to the baseline risk for cancer
for the different categories of patients. Still, there is a
potential for a complex selection mechanism for receiv-
ing a THR and also for receiving the different types of
Table 3 SIR and Cox model with time dependent covariates for the excess risk after 10 years follow-up comparing different types of
fixations
#hips #cancers Total Before 10 years After 10 years Cox model with time-dep. covariatesa
SIR (95% CI) SIR (95% CI) SIR (95% CI) HR b (95% CI) P
Total: 41,402 6167 1.06 (1.03–1.09) 1.06 (1.03–1.09) 1.02 (0.97–1.07)
Cemented 32,534 5060 1.05 (1.03–1.08) 1.06 (1.03–1.09) 0.99 (0.94–1.05) 1 (reference) –
Uncemented 6679 743 1.08 (1.00–1.16) 1.04 (0.94–1.13) 1.16 (1.02–1.30) 1.24 (1.05–1.46) 0.009
Hybrid 2189 364 1.11 (0.99–1.22) 1.09 (0.95–1.22) 1.12 (0.91–1.33) 1.07 (0.85–1.35) 0.55
< 55 years: 3374 246 0.96 (0.84–1.08) 0.89 (0.74–1.04) 1.06 (0.86–1.26)
Cemented 1138 89 1.09 (0.86–1.31) 1.04 (0.77–1.32) 1.16 (0.77–1.56) 1 (reference) –
Uncemented 1967 139 0.89 (0.75–1.04) 0.80 (0.62–0.99) 1.00 (0.76–1.24) 1.19 (0.69–2.05) 0.54
Hybrid 269 18 0.96 (0.52–1.40) 0.85 (0.37–1.34) 1.27 (0.25–2.29) 1.31 (0.45–3.82) 0.62
55–64 years: 12,500 1664 1.06 (1.01–1.11) 1.00 (0.95–1.06) 1.16 (1.06–1.25)
Cemented 8480 1119 1.02 (0.96–1.08) 0.97 (0.90–1.04) 1.11 (1.00–1.22) 1 (reference) –
Uncemented 3219 418 1.15 (1.04–1.27) 1.08 (0.95–1.21) 1.29 (1.09–1.50) 1.07 (0.85–1.36) 0.56
Hybrid 801 127 1.15 (0.95–1.35) 1.13 (0.90–1.36) 1.16 (0.79–1.53) 0.93 (0.62–1.38) 0.71
65–74 years: 25,528 4257 1.07 (1.03–1.10) 1.09 (1.05–1.12) 0.96 (0.90–1.02)
Cemented 22,916 3852 1.06 (1.03–1.10) 1.09 (1.05–1.13) 0.95 (0.89–1.01) 1 (reference) –
Uncemented 1493 186 1.10 (0.94–1.26) 1.11 (0.93–1.29) 1.03 (0.72–1.35) 1.00 (0.71–1.43) 0.98
Hybrid 1119 219 1.10 (0.96–1.25) 1.09 (0.91–1.26) 1.09 (0.82–1.35) 1.12 (0.83–1.51) 0.46
Men: 13,954 2542 1.03 (0.99–1.07) 1.02 (0.97–1.07) 1,03 (0.95–1.10)
Cemented 10,423 2037 1.02 (0.98–1.07) 1.02 (0.97–1.07) 0,99 (0.91–1.08) 1 (reference) –
Uncemented 2748 343 1.04 (0.93–1.15) 0.98 (0.85–1.11) 1.15 (0.95–1.34) 1.41 (1.11–1.80) 0.004
Hybrid 783 162 1.13 (0.96–1.31) 1.11 (0.91–1.31) 1.15 (0.81–1.49) 1.11 (0.78–1.58) 0.58
Women: 27,448 3625 1.08 (1.05–1.12) 1.09 (1.05–1.13) 1.02 (0.96–1.08)
Cemented 22,111 3023 1.08 (1.04–1.12) 1.09 (1.04–1.14) 1.00 (0.93–1.06) 1 (reference) –
Uncemented 3931 400 1.12 (1.01–1.23) 1.09 (0.96–1.22) 1.17 (0.97–1.36) 1.09 (0.87–1.36) 0.47
Hybrid 1406 202 1.09 (0.94–1.24) 1.07 (0.89–1.24) 1.10 (0.80–1.39) 1.06 (0.78–1.43) 0.72
a Adjusted for current age, gender, diagnosis, and a second primary or revision prosthesis operation
b,c The estimates are hazard ratios (HR)
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THR, which we are not able to adjust for. Hypothetic-
ally, receiving a THR can increase the attention to own
health. Subsequently, this can lead to more visits for
medical care (e.g. general practitioner), which may in-
crease the number of tests and also the probability of be-
ing tested for cancer. This would particularly be the case
for prostate cancer in men.
Recently, Cartilage Oligomeric Matrix Protein (COMP),
which plays an important role in the organization of the
extracellular matrix of cartilage, has been identified as a
potent driver of the progression of prostate cancer, acting
in an anti-apoptotic fashion by interfering with the Ca2+
homeostasis of cancer cells [30]. In a retrospective case
control series in prostate cancer patients with and without
osteoarthritis, this condition was identified as an inde-
pendent risk factor for metastatic disease. However, when
joint arthroplasty was included in the model, osteoarthritis
was no longer an independent risk factor [31]. It is un-
likely that this association can explain the small increase
in cancer risk in men with uncemented compared to
cemented THR in our study.
The common analytical approach to study cancer risk
for THR and TKA patients is to compare the observed
cancer risk for arthroplasty patients with cancer rates in
the general population. When SIRs are used to compare
the cancer risk for the patients studied with the cancer
risk in the population, it is assumed that prosthesis pa-
tients are comparable to the general population. Previ-
ous studies find no increase in risk for cancer after an
arthroplasty compared to the general population [6–18].
Overall, this agrees with our finding, using the same ana-
lyses techniques.
From studies of secondary cancer related to anti-
neoplastic treatment, it is known that the latency from
the first to the subsequent malignant tumour is 10 years
or more [32, 33]. In the regression models in this study,
we took into consideration that the development of can-
cer related to arthroplasty can take at least one decade,
Table 4 Cox model with time dependent covariates for subgroups of gender and age groups
# hips #
cancer
Total Before 10 years After 10 years Cox model with timedep covariates
SIR (95% CI) SIR (95% CI) SIR (95% CI) HR (95% CI) P
Men
< 55 years
Cemented 471 35 1.16 (0.78–1.55) 1.11 (0.63–1.58) 1.23 (0.59–1.88) 1 (reference)
Uncemented 896 68 0.98 (0.75–1.21) 1.00 (0.67–1.33) 0.94 (0.62–1.26) 0.91 (0.39–2.08) 0.82
Hybrid 121 7 0.87 (0.23–1.52) 0.68 (0.01–1.35) 1.37 (0.00–2.92) 1.66 (0.32–8.63) 0.55
55–64 years
Cemented 2870 463 0.99 (0.90–1.08) 0.93 (0.82–1.03) 1.10 (0.93–1.26) 1 (reference)
Uncemented 1281 184 1.03 (0.88–1.18) 0.91 (0.74–1.08) 1.26 (0.97–1.54) 1.26 (0.89–1.79) 0.19
Hybrid 287 52 1.05 (0.77–1.34) 1.03 (0.69–1.36) 1.09 (0.56–1.62) 0.94 (0.50–1.74) 0.83
65–74 years
Cemented 7082 1539 1.03 (0.98–1.08) 1.04 (0.98–1.10) 0.94 (0.84–1.04) 1 (reference)
Uncemented 571 91 1.12 (0.89–1.35) 1.09 (0.84–1.35) 1.18 (0.65–1.71) 1.14 (0.68–1.90) 0.63
Hybrid 375 103 1.20 (0.97–1.43) 1.20 (0.93–1.46) 1.17 (0.71–1.63) 1.09 (0.69–1.72) 0.70
Women
< 55 years
Cemented 667 54 1.04 (0.77–1.32) 1.00 (0.67–1.34) 1.12 (0.63–1.61) 1 (reference)
Uncemented 1071 71 0.83 (0.63–1.02) 0.67 (0.45–0.89) 1.06 (0.72–1.41) 1.44 (0.70–2.98) 0.32
Hybrid 148 11 1.03 (0.42–1.63) 0.98 (0.30–1.66) 1.18 (0.00–2.52) 1.07 (0.25–4.50) 0.93
55–64 years
Cemented 5610 656 1.04 (0.96–1.12) 1.00 (0.90–1.09) 1.12 (0.98–1.27) 1 (reference)
Uncemented 1938 234 1.27 (1.11–1.43) 1.24 (1.04–1.43) 1.33 (1.30–1.36) 0.94 (0.68–1.29) 0.69
Hybrid 514 75 1,22 (0,95-1,50) 1,21 (0,89-1,54) 1,21 (0,71-1,72) 0.91 (0.54–1.54) 0.73
65–74 years
Cemented 15,834 2313 1.09 (1.04–1.13) 1.12 (1.06–1.17) 0.95 (0.88–1.03) 1 (reference)
Uncemented 922 95 1.08 (0.86–1.3) 1.12 (0.86–1.38) 0.93 (0.54–1.32) 0.90 (0.56–1.44) 0.65
Hybrid 744 116 1.03 (0.84–1.21) 0.99 (0.77–1.21) 1.04 (0.72–1.36) 1.14 (0.78–1.68) 0.50
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and that cancer diagnoses during the first years after a
THR operation are most likely related to factors other
than the arthroplasty itself. To compare the different
types of fixations, we therefore used baseline cancer risk
at the first 10 years follow-up as a reference. In these
analyses we thus compared the difference in cancer risk
between different types of fixations, and other factors,
adjusting for the crucial selection for receiving the THR.
We found an increased cancer risk for patients with
two uncemented prostheses components, compared to
patients where both prostheses components were
cemented. Patient with hybrid prostheses had not a sta-
tistically increased risk for cancer compared to patients
with two cemented components.
In analyses of cancer after THR, death is a competing
risk. For the present analyses we did not take competing
risks into account. The reason is that since there are dif-
ferences in selection mechanisms between the different
prosthesis, which will be apparent in analyses with death
as endpoint, death may also be a collider in causal ter-
minology when we study the risk for receiving cancer.
Accordingly, using models for competing risks, a false
and elevated risk between the types of THR and cancer
was present (analyses not shown). The relative differ-
ences in the SIRs in our analyses correspond to the find-
ings from the Cox model with time-dependent
adjustment, which we consider strengthen our findings.
There has been a concern about cancer risks associ-
ated with metal on metal articulations for THRs [9, 10,
14, 34], but other and newer types of articulations
should also be studied [35]. Articulation has not been in-
cluded in the present study since the majority of THR
prostheses in the Norwegian Arthroplasty Register have
a metal head and polyethylene cup, and other articula-
tions have lower numbers or shorter follow-up [22].
Metal-on-metal has rarely been used in Norway in the
study period. Only approximately 200 cemented and less
than 200 uncemented implants of this type, most of
which with small heads (< 32mm) were used in the time
period studied [36]. Metal on metal resurfacing implants
were excluded from the study, because this type of THR
is a marginal problem in this study, and omitting these
implants would not alter our findings.
Conclusion
In the present study, we found no increased risk for can-
cer in THR patients compared to the general population.
However, we found a small increased risk for cancer
after insertion of THR where both components were
uncemented, compared to prostheses where both were
cemented. In gender-stratified analysis, this increased
risk was only found for men, but not found in age-
stratified analysis for men. The difference was small and
prone to unmeasured confounding. The risk for cancer
after joint replacements and possible mechanisms re-
lated to cancer for patients with musculoskeletal diseases
and/or joint replacements should be studied further.
Surveillance of new products, materials and prostheses,
with respect to rare and adverse outcomes like cancer, is
important, also in the future.
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